Core Insights - BD (Becton, Dickinson and Company) has launched the new BD® Intraosseous Vascular Access System, designed for rapid delivery of fluids or medication in critical emergency situations [1][2][3] - The system allows for quick access to the circulatory system for both adult and pediatric patients, enhancing emergency care capabilities [2][3] Product Features - The BD® IO System is the only intraosseous device that can be placed after the extension set is attached and includes integrated passive needle tip safety to protect against needlestick injuries [2] - It features a rechargeable battery that extends the drill's life up to 12 times compared to non-rechargeable competitive drills, along with a multi-light battery indicator for instant battery status [2] - The device can accommodate a broad range of patients with five needle lengths and can be stabilized on various anatomical contours [2] Clinical Significance - In emergency situations, the placement of an intraosseous (IO) line is twice as likely to be successful compared to peripheral IV or central venous catheter placement, especially in patients with low or no palpable blood pressure [3] - Trained inserters achieve a 93-97 percent success rate in IO placement, indicating the reliability of the procedure [3] Availability - The BD® IO System is now commercially available to customers in the U.S. [4]

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can be a tough task.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, it's pretty easy to find cutting-edge growth stocks with the he ...

Core Viewpoint - Becton, Dickinson and Company (BDX) has launched the BD OMICS-One XT Library Preparation Reagent Kits, which are expected to enhance automation and efficiency in single-cell discovery studies, thereby strengthening BD's position in the biosciences market [1][3][6]. Company Developments - The BD OMICS-One XT Library Preparation Reagent Kits are designed to automate the labor-intensive process of constructing DNA libraries, which is crucial for single-cell discovery studies [6][7]. - The collaboration with Hamilton has resulted in the integration of the BD OMICS-One XT WTA Assay with the Hamilton Microlab NGS STAR automated liquid handling platform, facilitating easier adoption in existing laboratory workflows [2][7]. - BD's management anticipates that the new automated solution will lead to more consistent results and reduced variability in research outcomes, particularly in oncology and immunology [7][8]. Market Performance - Following the product launch, BDX shares increased by nearly 1.5%, closing at $240.02, indicating positive market sentiment [4]. - BD currently has a market capitalization of $69.38 billion and an earnings yield of 5.9%, which is higher than the industry average of 5.5% [5]. Industry Prospects - The global single-cell analysis market was valued at $4.34 billion in 2023 and is projected to grow at a CAGR of 18.7% from 2024 to 2030, driven by advancements in disease diagnosis and technological innovations [9]. - The launch of the BD OMICS-One XT Library Preparation Reagent Kits is expected to significantly contribute to BD's growth in this expanding market [9].

Automation-Ready Reagents Used with the Hamilton Robotics Liquid-Handler Streamlines and Helps Accelerate Lab Work Leading to Genomic Sequencing FRANKLIN LAKES, N.J., Oct. 14, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the commercial launch of the first in a family of high-throughput, robotics-compatible reagent kits that will enable automation to ensure greater consistency and increased efficiency of large-scale, single- ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Becton Dickinson (BDX) . This company, which is in the Zacks Medical - Dental Supplies industry, shows potential for another earnings beat. This medical device manufacturer has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for th ...

Core Points - BD (Becton, Dickinson and Company) will report its financial results for the fiscal 2024 fourth quarter and full year on November 7, 2024 [1][2] - An audio webcast will be hosted by BD management at 8 a.m. ET on the same day to discuss the financial results and provide updates on operations and strategy [3] - BD has scheduled webcasts for its fiscal year 2025 quarterly financial results on February 6, May 1, July 31, and November 6, 2025 [3] Company Overview - BD is a leading global medical technology company focused on improving medical discovery, diagnostics, and care delivery [4] - The company employs over 70,000 individuals and is committed to enhancing the safety and efficiency of healthcare delivery [4] - BD collaborates with organizations worldwide to tackle significant global health challenges and improve healthcare outcomes [4]

Becton, Dickinson and Company (BDX) , popularly known as BD, is well-poised for growth in the coming quarters, courtesy of its solid product portfolio. The optimism led by a solid third-quarter fiscal 2024 performance and a few strategic deals are expected to contribute further. However, macroeconomic concerns and stiff competition persist. Over the past year, this Zacks Rank #3 (Hold) stock has lost 7.7% against the 0.6% rise of the industry and the S&P 500's 33.7% growth. The renowned medical technology c ...

No admission of liability or wrongdoing; settlement structured to eliminate uncertainty for all stakeholders related to settled cases. Settlement amount within current product litigation reserve and will be paid out over a multi-year period. Settlement will not change BD's cash flow goals or capital allocation strategy. FRANKLIN LAKES, N.J., Oct. 2, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has reached an agreement to ...

FRANKLIN LAKES, N.J., Sept. 26, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new data that highlights how its advanced artificial intelligence technology can help health systems better identify incidents of controlled substance diversion in the operating room. New data highlights how advanced artificial intelligence technology can help health systems better identify incidents of controlled substance diversion in the operati ...

LE PONT-DE-CLAIX, France, Sept. 18, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial release of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe and the latest capacity expansion of the BD Neopak™ Glass Prefillable Syringe platform to serve the growing market for biologic therapies. BD announces the commercial release of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe and the latest capacity expansion of the BD Ne ...